Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 35

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 35
---
 95118. Our telephone number is (408) 708-9808. Information about us is also available at our website at https://www.anixa.com/. However, the information in our website is not a part of this prospectus and is not incorporated by reference.

| 20 |

The information in this prospectus is not complete and may be changed. We may not sell the securities until the Registration Statement filed with the Securities and Exchange Commission, of which this prospectus is a part, is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED SEPTEMBER 10, 2025

Prospectus

ANIXA BIOSCIENCES, INC.

Up to $100,000,000

Common Stock</div>

We have entered into a Controlled Equity Offering SMSales Agreement with Cantor Fitzgerald & Co. (“Cantor”) relating to the sale of our common stock offered by this prospectus. In accordance with the terms of the Controlled Equity Offering SMSales Agreement, we may offer and sell up to $100,000,000 of shares of our common stock, $0.01 par value per share, from time to time through or to Cantor acting as agent or principal. We have previously sold $5,457,367.13 of shares pursuant to the Controlled Equity Offering SMSales Agreement in connection with our at-the-market offering program registered on our prior registration statement on Form S-3 (File No. 333-267369).

Our common stock is listed on The NASDAQ Capital Market under the symbol “ANIX.” The last reported sale price of our common stock on the NASDAQ Capital Market on September 9, 2025 was $2.98 per share. The aggregate market value of our outstanding common stock held by non-affiliates was $107,219,609 based on 32,916,915 shares of outstanding common stock, of which 31,168,491 shares are held by non-affiliates, and a per share price of $3.44 which was the closing sale price of our common stock as quoted on the NASDAQ Capital Market on July 18, 2025.

Sales of our common stock, if any, under this prospectus may be made in sales deemed to be “at the market equity offerings” as defined in Rule 415 promulgated